Published in J Urol on August 01, 2005
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (2016) 3.06
Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. J Clin Oncol (2014) 2.23
Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol Cell Proteomics (2012) 1.72
Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol (2008) 1.60
Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol (2006) 1.41
Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol (2008) 1.24
Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer (2008) 1.16
From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol Cancer (2009) 1.03
Cost analysis of two follow-up strategies for localized kidney cancer: a Canadian cohort comparison. Can Urol Assoc J (2010) 0.93
Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status. Int J Clin Oncol (2013) 0.92
Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers. Mol Cancer Ther (2010) 0.91
Renal cell carcinoma with synchronous metastasis to the calcaneus and metachronous metastases to the ovary and gallbladder. Case Rep Med (2011) 0.86
Potentially curable recurrent disease after surgically managed non-metastatic renal cell carcinoma in low-, intermediate- and high-risk patients. World J Urol (2016) 0.86
Evaluation of long-term outcome for patients with renal cell carcinoma after surgery: analysis of cancer deaths occurring more than 10 years after initial treatment. Int J Clin Oncol (2013) 0.83
Patterns of surveillance imaging after nephrectomy in the Medicare population. BJU Int (2015) 0.83
Prognostic role of microvessel density in patients with renal cell carcinoma: a meta-analysis. Int J Clin Exp Pathol (2014) 0.82
Predictive models for the practical management of renal cell carcinoma. Nat Rev Urol (2012) 0.79
Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma. Curr Oncol (2009) 0.78
Solitary renal fossa recurrence of renal cell carcinoma after nephrectomy. Rev Urol (2014) 0.78
Chest X-ray in the follow-up of renal cell carcinoma. World J Urol (2013) 0.77
Postoperative surveillance imaging for patients undergoing nephrectomy for renal cell carcinoma. Urol Oncol (2015) 0.77
Challenges in RCC Imaging: Renal Insufficiency, Post-Operative Surveillance, and the Role of Radiomics. Kidney Cancer J (2015) 0.77
Molecular profiling of small renal masses: Current status and future directions. Indian J Urol (2009) 0.75
Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma? Cancer Res Treat (2014) 0.75
Comparison of guideline recommendations with daily practice in patients with renal cell carcinoma. Eur J Med Res (2010) 0.75
Limited use of surveillance imaging following nephrectomy for renal cell carcinoma. Urol Oncol (2015) 0.75
A three-molecule score based on Notch pathway predicts poor prognosis in non-metastasis clear cell renal cell carcinoma. Oncotarget (2016) 0.75
Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort. Can Urol Assoc J (2015) 0.75
Long lasting response to second-line everolimus in kidney cancer. World J Clin Cases (2013) 0.75
Locally advanced renal cell carcinoma. Can Urol Assoc J (2007) 0.75
Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement. J Multidiscip Healthc (2015) 0.75
Low yield of surveillance imaging after surgery for T1 kidney cancer. World J Urol (2015) 0.75
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol (2017) 0.75
[Urological therapy of renal cell cancer]. Wien Med Wochenschr (2008) 0.75
Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma. Sci Rep (2017) 0.75
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol (2012) 4.58
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2011) 4.52
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am (2003) 3.44
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol (2007) 3.26
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol (2004) 3.06
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Flexible ureteroscopy and laser lithotripsy for multiple unilateral intrarenal stones. Eur Urol (2008) 2.97
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol (2002) 2.91
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88
Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res (2005) 2.67
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45
Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol (2009) 2.43
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 2.38
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int (2008) 2.35
Systemic therapy in renal cell carcinoma: advancing paradigms. Oncology (Williston Park) (2012) 2.25
Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol (2011) 2.10
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol (2009) 2.05
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol (2005) 2.05
Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol (2005) 2.05
Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs (2010) 2.01
Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod Pathol (2005) 1.89
Secondary hormonal therapy for advanced prostate cancer. J Urol (2006) 1.86
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res (2006) 1.86
p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol (2007) 1.81
Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One (2012) 1.80
Flexible ureteroscopy and laser lithotripsy for single intrarenal stones 2 cm or greater--is this the new frontier? J Urol (2008) 1.80
Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol (2009) 1.75
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer (2008) 1.70
Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol (2004) 1.70
Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int (2007) 1.69
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol (2007) 1.67
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol (2004) 1.65
S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell (2012) 1.64
Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. Cancer (2011) 1.64
Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. J Urol (2011) 1.63
Tumor biology and prognostic factors in renal cell carcinoma. Oncologist (2011) 1.62
Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res (2007) 1.61
Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer (2010) 1.61
Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. Urology (2004) 1.60
Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol (2005) 1.60
Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol (2003) 1.60
Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer (2005) 1.59
Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol (2003) 1.59
Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience. J Urol (2008) 1.59
Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer (2008) 1.58